Ovarian cancer: front-line standard treatment in 2008

Vasey, P. A. (2008). Ovarian cancer: front-line standard treatment in 2008. In: Educational Book of the 33rd ESMO Congress 2008. ESMO 2008: 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, (vii61-vii66). 12-16 September, 2008. doi:10.1093/annonc/mdn479

Author Vasey, P. A.
Title of paper Ovarian cancer: front-line standard treatment in 2008
Conference name ESMO 2008: 33rd European Society for Medical Oncology Congress
Conference location Stockholm, Sweden
Conference dates 12-16 September, 2008
Proceedings title Educational Book of the 33rd ESMO Congress 2008   Check publisher's open access policy
Journal name Annals of Oncology   Check publisher's open access policy
Place of Publication Oxford, United Kingdom
Publisher Oxford University Press
Publication Year 2008
Sub-type Fully published paper
DOI 10.1093/annonc/mdn479
Open Access Status Not yet assessed
ISSN 0923-7534
Volume 19
Issue Supp. 7
Start page vii61
End page vii66
Total pages 6
Language eng
Formatted Abstract/Summary
In the early part of the 21st century, the estimated annual worldwide incidence of ovarian cancer is over 200,000 with approximately 125,000 women dying from this disease. Despite considerable progress during the last 30 years, prognosis generally remains poor. Patients with stage I disease may anticipate a 5-year survivorship >75%, but those diagnosed with stage 4 disease have a <10% prospect of reaching this milestone.

Treatment of ovarian cancer is a prime example of multidisciplinary care, requiring close integration of surgery and medical therapy. Radiation has a relatively minor role. Surgery is generally undertaken first, wherein the gynecologic oncologist attempts to perform an ‘optimal’ cytoreductive procedure to debulk the cancer, with the aim of leaving no macroscopic tumour behind. Virtually all patients then receive a course of ‘adjuvant’ chemotherapy. Surgical treatment followed by chemotherapy aims to deliver a substantial period of remission, even in advanced disease. Unfortunately, the vast majority of patients with advanced disease will then experience a recurrence, which can be treated by further surgery in some cases and further chemotherapy in most. Patients may receive many classes of chemotherapeutic agents before their disease becomes truly drug resistant.
Subjects 2700 Medicine
2720 Hematology
2730 Oncology
Q-Index Code E1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Conference Paper
Sub-type: Fully published paper
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 27 Nov 2013, 11:57:15 EST by System User on behalf of School of Medicine